Sheller, P.C. currently is investigating cases involving pregnant women who took the drug Topamax® during their first trimester of pregnancy and gave birth to a baby with an oral cleft deformity (split cleft or palate) or other serious fetal deformities.
Topamax and generic versions (topiramate) are approved for use in the United States to treat epilepsy and severe migraine headaches. The Food and Drug Administration (FDA) recently announced that it is reclassifying Topamax from a Pregnancy Category C to a more serious Category D after recent North American Antiepileptic Drug (NAAED) Pregnancy Registry data indicated a heightened risk of birth defects such as cleft lips and cleft palates among babies born to women who took the drug during early pregnancy.
Sheller, P.C. is well positioned to evaluate these cases and protect the rights of those who may be injured by the drug. Last year, Jamie Sheller, Esq. represented plaintiffs in the bellwether trial Kilker v. GlaxoSmithKline, which garnered a $2.5 million jury verdict in a trial linking the antidepressant Paxil to birth defects.
If you have, or someone you know has, given birth to a baby with a cleft deformity or other skeletal fetal deformities after taking Topamax or topiramate in your first trimester of pregnancy, call Sheller, P.C. at 1-800-883-2299 to have your case evaluated.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.